* STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO)...
* 78-Week results from Phase III randomized controlled trial (RCT) including switching data from ...
* Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-appro...
* Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy o...
We are advised by Celltrion USA that journalists and other readers should disregard the news releas...
* Adalimumab-aaty was first approved by the Food and Drug Administration on May 23, 2023 and beca...
* Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-te...
* Data presentations including the extended LIBERTY studies to highlight the long-term treatment ...
* Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) * Branded and unbran...